Business context and reporting period
USANA Health Sciences, Inc. develops and sells nutrition, personal care and skincare products primarily through direct selling. This is its Form 10-K for the fiscal year ended December 30, 2023, compared mainly with the fiscal year ended December 31, 2022. Although the request metadata says “2022 Q4,” the filing covers full-year 2023; it does not provide a clear standalone fourth-quarter financial summary.
The company operated in 25 markets and reported approximately 483,000 active Customers at year-end, down 1.4% from 490,000. China was its largest market, contributing 46.4% of net sales; 89.6% of sales were generated outside the United States. USANA began operations in India late in the fourth quarter.
Key financial metrics
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net sales | $921.0 million | $998.6 million |
| Gross profit / gross margin | $744.3 million / 80.8% | $804.7 million / 80.6% |
| Operating earnings | $93.1 million | $107.6 million |
| Net earnings | $63.8 million | $69.4 million |
| Diluted EPS | $3.30 | $3.59 |
| Cash flow from operations | $70.6 million | $103.9 million |
| Cash and cash equivalents at year-end | $330.4 million | $288.4 million |
Associate incentives were $394.3 million, or 42.8% of sales, versus $434.8 million, or 43.5%, in 2022. Selling, general and administrative expense was $257.0 million, down $5.3 million, but rose as a share of sales because revenue declined. The effective income tax rate increased to 37.7% from 36.2%.
Current assets were $417.7 million and current liabilities $118.8 million at year-end. Stockholders’ equity was $497.2 million. USANA had no outstanding borrowings on its $75 million revolving credit facility and $0.8 million outstanding on local lines of credit. Operating lease liabilities totaled $12.4 million. Management said available cash, operating cash flow and credit availability should meet ordinary-course needs for the foreseeable future.
Material changes versus the prior comparable period
- Sales fell 7.8% ($77.6 million); management attributed the decline to difficult economic conditions, customer and purchasing trends, and an estimated $27.8 million unfavorable currency effect. Sales declined 5.0% excluding currency effects.
- Net earnings declined 8.0% and diluted EPS fell from $3.59 to $3.30. Operating earnings decreased by $14.5 million.
- Sales declined in each reported geographic region: Asia Pacific fell 7.7% and Americas and Europe fell 8.2% in reported dollars. Greater China generated $475.1 million; Southeast Asia Pacific, $163.9 million; North Asia, $101.4 million; and Americas and Europe, $180.6 million.
- Gross margin improved by 20 basis points, reflecting lower inventory valuation adjustments and price increases, partly offset by higher material costs, currency effects and lower-sales deleverage.
- Operating cash flow decreased by $33.3 million, partly reflecting a $30.0 million cash outflow from changes in other liabilities. Cash increased by $42.0 million after operating, investing and financing cash flows and currency effects.
Outlook, commentary and risks
No specific 2024 revenue or earnings guidance is provided in the supplied filing text. Management’s priorities include increasing active Customers, enhancing digital commerce and Associate engagement, developing products, growing India, focusing on China, expanding in-house food production and evaluating acquisitions. Management expects to increase investment in early-stage research. It also warned that inflationary pressures on materials, wages, energy and transportation, as well as the cost of capital, could continue or increase in 2024.
Significant risks include dependence on the direct-selling model and independent Associates; customer declines and intense competition; foreign-exchange exposure; and regulatory uncertainty, especially in China. BabyCare’s China business model has not been approved by the Chinese government, and direct-selling license expansion is constrained while the government’s application review process remains suspended. China generated 46.4% of company sales.
Financial reporting controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 30, 2023, due to material weaknesses in IT general controls involving user access, program changes and computer operations. KPMG issued an adverse opinion on internal control effectiveness, while issuing an unqualified opinion on the financial statements. No financial-statement misstatements or restatements were identified. Management expects remediation before fiscal year-end 2024, but the weaknesses were not yet remediated.
Other notable items: USANA repurchased $11.6 million of stock during 2023 and had $71.2 million of authorized repurchases remaining at year-end. It reported $44.7 million of contractual obligations, including leases and other commitments. Management said ordinary-course litigation was not expected to have a material adverse effect, but some contingencies could not currently be estimated.
Important facts for investors to verify
- Whether active Customers, sales and earnings stabilize or recover, particularly in China and other declining markets.
- Progress in remediating IT-control material weaknesses and whether controls operate effectively in subsequent reporting periods.
- China regulatory developments, BabyCare compliance and licensing, and restrictions on remitting China earnings.
- Cash-flow sustainability, working-capital movements, and compliance headroom under the credit facility’s EBITDA and leverage covenants.
- Whether inflation, currency movements and customer purchasing behavior affect margins and the company’s 2024 plans; the filing gives no numerical financial guidance.